Sample 1 consisted of 167 veterans recruited at a VA Healthcare System for a study designed to validate both the PTSD Checklist for DSM–5 (PCL-5; Weathers, et al., 2013 ) and the CAPS-5 (Weathers, Blake, et al., 2013 ). A subset of these data was used previously to validate the PCL-5 (Bovin et al., 2016 (link)). This study followed the second version of the Quality Assessment of Diagnostic Accuracy Studies guidelines (QUADAS-2; Whiting et al., 2011 (link)), which minimizes the influence of various sources of bias that can affect diagnostic utility studies (see Bovin et al., 2016 (link)). This study was open to all veterans who were aged 18 or older who could read written materials in English. Potential participants were screened for trauma exposure and PTSD symptoms with the Brief Trauma Questionnaire (Schnurr et al., 2002 ) and Primary Care PTSD Screen (PC-PTSD; Prins et al., 2003 ), administered during an initial phone contact with a trained research assistant. Individuals who reported experiencing at least one PTSD Criterion A event and at least one PTSD symptom in the last 30 days were included in this study. The requirement of at least one PTSD symptom was applied to minimize restriction of range in scores on the CAPS-5 and other PTSD measures.
Participants for Sample 1 were recruited into one of three phases: Phase 1 (n = 31), Phase 2 (n = 61), and Phase 3 (n = 75). In Phase 1, CAPS-IV versus CAPS-5 comparisons were based on 30 participants with complete data (original interviewer’s ratings) for both interviews; one participant was excluded because he did not complete the CAPS-IV. Interrater reliability analyses were based on 27 participants for CAPS-IV and 28 for CAPS-5 for whom audio recorded interviews were available. For all Phase 1 participants, the index event for symptom inquiry met Criterion A for both DSM–IV and DSM–5 PTSD criteria. In Phase 2, test–retest analyses were based on 60 participants with complete data for both administrations of the CAPS-5; one participant was excluded because he did not complete the CAPS-5.
Participants from Phases 1 through 3 were combined for internal consistency and convergent and discriminant validity analyses. Two participants in Phase 3 did not complete the CAPS-5 and were excluded from all subsequent analyses. Thus, the combined sample for these analyses was 165, including 31 from Phase 1, 61 from Phase 2, and 73 from Phase 3 (seeTable 1 ).
Sample 2 consisted of 207 male veterans who completed the baseline assessment of an ongoing clinical trial (Sloan, Unger, & Gayle Beck, 2016 (link)). Eligible veterans were invited to complete an initial assessment (see Sloan et al., 2016 (link) for a detailed overview of study procedures). The only inclusion criteria for the present study were being a male veteran with an index event that met DSM–5 Criterion A, and self-identifying as being appropriate for a PTSD treatment study. SeeTable 1 for characteristics of the sample.
Participants for Sample 1 were recruited into one of three phases: Phase 1 (n = 31), Phase 2 (n = 61), and Phase 3 (n = 75). In Phase 1, CAPS-IV versus CAPS-5 comparisons were based on 30 participants with complete data (original interviewer’s ratings) for both interviews; one participant was excluded because he did not complete the CAPS-IV. Interrater reliability analyses were based on 27 participants for CAPS-IV and 28 for CAPS-5 for whom audio recorded interviews were available. For all Phase 1 participants, the index event for symptom inquiry met Criterion A for both DSM–IV and DSM–5 PTSD criteria. In Phase 2, test–retest analyses were based on 60 participants with complete data for both administrations of the CAPS-5; one participant was excluded because he did not complete the CAPS-5.
Participants from Phases 1 through 3 were combined for internal consistency and convergent and discriminant validity analyses. Two participants in Phase 3 did not complete the CAPS-5 and were excluded from all subsequent analyses. Thus, the combined sample for these analyses was 165, including 31 from Phase 1, 61 from Phase 2, and 73 from Phase 3 (see
Sample 2 consisted of 207 male veterans who completed the baseline assessment of an ongoing clinical trial (Sloan, Unger, & Gayle Beck, 2016 (link)). Eligible veterans were invited to complete an initial assessment (see Sloan et al., 2016 (link) for a detailed overview of study procedures). The only inclusion criteria for the present study were being a male veteran with an index event that met DSM–5 Criterion A, and self-identifying as being appropriate for a PTSD treatment study. See